What is Semaglutide?
Semaglutide is a once-weekly GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves blood-sugar control. Brand-name versions include Ozempic (type-2 diabetes) and Wegovy (chronic weight management), both FDA-approved and manufactured by Novo Nordisk. Compounded Semaglutide is prepared by 503A licensed compounding pharmacies using FDA-grade active pharmaceutical ingredient.
Semaglutide produces an average 10–15% body weight reduction in eligible patients over 68 weeks of treatment — a transformational outcome for a once-weekly injection.
Who qualifies for Semaglutide in Rockwall County?
Eligibility is determined by your BestRx provider after reviewing your intake. The general qualifying criteria match those of other GLP-1 medications.
- BMI 30+ (or 27+ with comorbidity)
- Age 18–75
- No personal/family history of MTC or MEN2
- Not currently pregnant or breastfeeding
- Comfortable with weekly subcutaneous self-injection
How Rockwall County patients use Semaglutide
Semaglutide titration follows a slow ramp to minimize gastrointestinal side effects. Your provider starts you at 0.25 mg weekly and increases every 4 weeks based on tolerance and response, up to a target dose of 2.4 mg weekly.
- Week 1–4: 0.25 mg weekly
- Week 5–8: 0.5 mg weekly
- Week 9–12: 1.0 mg weekly
- Week 13–16: 1.7 mg weekly
- Week 17+: 2.4 mg weekly (target maintenance dose)
Semaglutide side effects
The most common side effects are mild gastrointestinal — nausea, occasional constipation, and reduced appetite. These typically improve as your body adapts. Serious side effects (pancreatitis, gallbladder issues, rare thyroid effects) are uncommon but reinforce the importance of provider oversight — which is why BestRx will not prescribe Semaglutide without a Texas-licensed clinician reviewing your full intake.
Semaglutide vs Tirzepatide — which is better for Rockwall County patients?
Both work. Tirzepatide produces somewhat larger average weight loss (15–22% vs 10–15%) but Semaglutide is the longer-studied option with broader real-world data. Semaglutide tends to be a better starting choice for patients with smaller weight goals, prior GLP-1 sensitivity, or budget considerations. Your BestRx provider will recommend based on your full clinical picture.
Tirzepatide vs Semaglutide — Which Is Right For You?
Tirzepatide and Semaglutide are the two most-prescribed compounded GLP-1 medications in the United States. Both are administered as once-weekly subcutaneous injections and both produce significant weight loss in eligible patients — but they work slightly differently and one is often a better fit depending on your starting weight, response to GLP-1s, and budget.
| Feature | Tirzepatide | Semaglutide |
|---|---|---|
| Class | Dual GIP + GLP-1 receptor agonist | GLP-1 receptor agonist (single) |
| Average loss (12 mo) | 15–22% of body weight | 10–15% of body weight |
| Dosing | 2.5 → 15 mg weekly titration | 0.25 → 2.4 mg weekly titration |
| Frequency | Once weekly | Once weekly |
| Onset of appetite reduction | Days 2–5 | Days 4–10 |
| Best for | Higher starting BMI, stronger appetite | Moderate weight goals, prior GLP-1 tolerance |